Case Study: Kimberly-Clark
part of Chime Communications plc
The Bell Pottinger Group: what could we do for you?
To launch InteguSeal to the European market as a novel antimicrobial preoperative treatment for the reduction of surgical site infections
Who did we need to speak to?
• Orthopaedic, Cardiothoracic and Vascular Surgeons from the UK, France and Germany
What was the story?
• Two to five per cent of patients undergoing surgery were at risk from surgical site infections; costing health organisations worldwide in excess of £2000 per infection. InteguSeal prevents microbial migration and infection by immobilising bacteria on the skin.
How was it told?
• Through articles by Key Opinion Leaders in the prominent specialist Pan-European and local language healthcare journals.
Result: Extensive coverage of InteguSeal obtained discussing the introduction of the technology, cost savings and infection reduction.
Who did we need to speak to?
• Orthopaedic, Cardiothoracic and Vascular Surgeons from the UK, France and Germany
What was the story?
• Two to five per cent of patients undergoing surgery were at risk from surgical site infections; costing health organisations worldwide in excess of £2000 per infection. InteguSeal prevents microbial migration and infection by immobilising bacteria on the skin.
How was it told?
• Through articles by Key Opinion Leaders in the prominent specialist Pan-European and local language healthcare journals.
Result: Extensive coverage of InteguSeal obtained discussing the introduction of the technology, cost savings and infection reduction.
 |
|
 |
 |
|
|
 |
|
|
|
|
|